| - |
C1inhibitor (human) |
Cinryze® |
Treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE). Routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment |
Rapid Review complete |
15th November 2012 |
 |
| - |
Cabazitaxel |
Jevtana® |
Treatment of patients with hormone-refractory metastatic prostate cancer previously treated with docetaxel-containing treatment regimen. |
NCPE Assessment process complete |
13th March 2012 |
|
| 21026 |
Cabotegravir/Rilpivirine |
Vocabria®/Rekambys® |
HIV-1 infection in adults who are virologically suppressed on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class. |
Rapid Review complete |
21st July 2021 |
|
| - |
Cabozantinib |
Cabometyx® |
Treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. |
NCPE Assessment process complete |
4th July 2018 |
|
| 22018 |
Cabozantinib/Nivolumab |
Cabometyx®/Opdivo® |
First-line treatment of advanced renal cell carcinoma in adults. |
Full HTA submission received from Applicant |
12th December 2024 |
|
| - |
Cabozantinib |
Cometriq® |
Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. For patients in whom Rearranged during Transfection (RET) mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision. |
Rapid Review complete |
13th August 2014 |
|
| 22063 |
Calcifediol monohydrate |
Dnord® |
Treatment of vitamin D deficiency (i.e., 25(OH)D levels <25 nmol/L) in adults, for the prevention of vitamin D deficiency in adults with identified risks such as in patients with malabsorption syndrome, chronic kidney disease mineral and bone disorder (CKD-MBD) or other identified risks, and as an adjuvant for the specific treatment of osteoporosis in patients with vitamin D deficiency or at risk of vitamin D deficiency. |
Rapid Review complete |
13th October 2022 |
|
| - |
Calcipotriol/Betamethasone dipropionate |
Enstilar® |
For the topical treatment of psoriasis vulgaris in adults |
Rapid review complete |
22nd June 2016 |
|
| - |
Camellia sinensis, folium (green tea leaf) |
Catephen® |
Cutaneous treatment of external genital and perianal warts (condylomataacuminata) in immunocompetent patients from the age of 18 years. |
Rapid Review complete |
10th July 2015 |
|
| - |
Canagliflozin |
Invokana® |
Treatment of type 2 diabetes as monotherapy or add-on combination therapy to other glucose-lowering medicinal products including insulin |
NCPE Assessment Process complete |
29th August 2014 |
|
| 20004 |
Cannabidiol |
Epidyolex® |
As adjunctive therapy of seizures associated with Dravet Syndrome in conjunction with clobazam, for patients two years of age and older. |
NCPE Assessment Process complete |
8th March 2021 |
|
| 20005 |
Cannabidiol |
Epidyolex® |
As adjunctive therapy of seizures associated with Lennox-Gastaut Syndrome in conjunction with clobazam, for patients two years of age and older. |
NCPE Assessment Process complete |
8th March 2021 |
|
| 21024 |
Cannabidiol |
Epidyolex® |
As adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older. |
Rapid Review complete |
8th July 2021 |
|
| 24015 |
Capivasertib |
Truqap® |
Capivasertib (Truqap®) is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. |
Awaiting full HTA submission from Applicant |
5th September 2024 |
|
| 22013 |
Caplacizumab |
Cablivi® |
Treatment of adults and adolescents aged 12 years and older weighing at least 40 kg experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression. |
Rapid Review complete |
31st March 2022 |
|
| 22049 |
Capmatinib |
Tabrecta® |
Advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. |
Rapid Review complete |
28th February 2024 |
|
| - |
Capsaicin |
Qutenza® |
Peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain. |
Rapid Review complete |
2nd July 2012 |
|
| 20054 |
Carfilzomib (in combination with daratumumab and dexamethasone) |
Kyprolis® |
In combination with daratumumab and dexamethasone (CAR+DAR+DEX) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. |
NCPE Assessment Process Complete |
3rd July 2024 |
|
| - |
Carfilzomib (in combination with dexamethasone) |
Kyprolis® |
For the treatment of adult patients with multiple myeloma who have received at least one prior therapy |
Rapid Review complete |
19th March 2019 |
|
| - |
Carfilzomib (in combination with lenalidomide and dexamethasone) |
Kyprolis® |
For the treatment of adult patients with multiple myeloma who have received at least one prior therapy. |
NCPE Assessment process complete |
19th October 2016 |
|
| 22035 |
Carglumic acid |
Ucedane® |
Treatment of hyperammonaemia due to N-acetyl-glutamate synthase (NAGS) primary deficiency. |
Rapid Review complete |
21st June 2022 |
|
| - |
Cariprazine |
Reagila® |
For the treatment of schizophrenia in adult patients. |
Rapid Review complete |
19th December 2018 |
|
| 21067 |
Casirivimab/imdevimab |
Ronapreve® |
For the treatment and prevention of COVID-19. |
Rapid Review complete |
1st February 2022 |
|
| - |
Catumazomab |
Removab® |
For the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible. |
Rapid Review complete |
6th September 2011 |
|
| 22003 |
Cefiderocol |
Fetcroja® |
For the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. Consideration should be given to official guidance on the appropriate use of antibacterial agents. |
Rapid Review complete |
5th June 2024 |
|
| - |
Ceftaroline |
Zinforo® |
For the treatment of adult patients with complicated Skin and Soft Tissue Infections (cSSTI) or Community Acquired Pneumonia (CAP). |
Rapid Review complete |
12th October 2012 |
|
| - |
Ceftazidime/avibactam |
Zavicefta® |
For the treatment of CIAI, cUTI, HAP (including VAP) and gram negative infections due to aerobic Gram-negative organisms in adult patients with limited treatment options. |
Rapid Review complete |
13th June 2017 |
|
| 21003 |
Ceftazidime/avibactam |
Zavicefta® |
For paediatric patients aged three months and older for the treatment of: Complicated intra-abdominal infection (cIAI); Complicated urinary tract infection (cUTI), including pyelonephritis; Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP); Infections due to aerobic Gram-negative organisms in patients with limited treatment options |
Rapid Review complete |
4th March 2021 |
|
| - |
Ceftolozane/tazobactam |
Zerbaxa® |
For the treatment of complicated urinary tract infections (cUTI), acute pyelonephritis and complicated intra-abdominal infections (cIAI) in adults. |
Rapid Review complete |
26th April 2016 |
|
| 21007 |
Cemiplimab |
Libtayo® |
Is indicated as monotherapy for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation. |
NCPE Assessment Process Complete |
24th October 2023 |
|
| 21025 |
Cenobamate |
Ontozry® |
Adjunctive treatment of focal onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least two anti-epileptic medicinal products. |
NCPE Assessment Process Complete |
6th July 2023 |
|
| - |
Ceritinib |
Zykadia® |
For the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib. |
Rapid Review complete |
22nd July 2015 |
|
| - |
Cerliponase alfa |
Brineura® |
For the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency. |
NCPE Assessment process complete |
26th March 2019 |
|
| - |
Certolizumab pegol |
Cimzia® |
For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
Rapid Review complete |
14th November 2019 |
|
| - |
Certolizumab pegol |
Cimzia® |
For the treatment of moderate to severe rheumatoid arthritis. |
NCPE Assessment Process complete |
2nd September 2010 |
|
| 23049 |
Chlormethine gel |
Ledaga® |
Chlormethine gel (Ledaga®) is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients. |
Rapid Review Complete |
11th November 2024 |
|
| 22033 |
Cholecalciferol |
Egostar® |
Prevention of vitamin D deficiency in adult patients with an identified risk, initial treatment of clinically relevant vitamin D deficiency, and as an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency. |
Rapid Review complete |
23rd June 2022 |
|
| 21062 |
Cholic acid |
Orphacol® |
For the treatment of inborn errors in primary bile acid synthesis due to 3β-Hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-Oxosteroid-5β-reductase deficiency in infants, children and adolescents aged one month to 18 years, and adults. |
Rapid Review complete |
12th January 2022 |
|
| - |
Ciclosporin |
Ikervis® |
For the treatment of severe keratitis in adult patients with dry eye disease (DED), which has not improved despite treatment with tear substitutes. |
Rapid Review complete |
18th January 2016 |
|
| 22021 |
Ciltacabtagene autoleucel |
Carvykti® |
For the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. |
NCPE Assessment Process Complete |
27th September 2023 |
|
| 24021 |
Ciltacabtagene autoleucel |
Carvykti® |
For the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor, have demonstrated disease progression on the last therapy, and are refractory to lenalidomide. |
Awaiting full HTA submission from Applicant |
4th September 2024 |
|
| - |
Cladribine |
Mavenclad® |
For the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features |
NCPE Assessment process complete |
20th July 2018 |
|
| - |
Clindamycin 1% with tretinoin 0.025% |
Treclinac® |
For the topical treatment of acne vulgaris when comedones, papules and pustules are present in patients 12 years or older. |
Rapid Review complete |
7th May 2014 |
|
| 19045 |
Co-enzyme Q10 |
CoQun® eye drops |
As a complementary add-on treatment to antihypertensive glaucoma therapy. |
Rapid Review complete |
13th January 2020 |
|
| - |
Cobimetinib |
Cotellic® |
For use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. |
NCPE Assessment process complete |
5th January 2017 |
|
| - |
Colesevelam |
Cholestagel® |
Hypercholesterolaemia |
Rapid Review complete |
22nd October 2010 |
|
| - |
Colistimethate sodium |
Colobreathe® |
For the management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older. |
Rapid Review complete |
28th June 2013 |
|
| - |
Collagenase Clostridium Histolyticum |
Xiapex® |
Treatment of Dupuytren’s contracture in adult patients with a palpable cord. |
Rapid Review complete |
9th June 2011 |
|
| 21017 |
Conestat alfa |
Ruconest® |
For the treatment of acute angioedema attacks in adults, adolescents, and children (aged 2 years and above) with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency. |
Rapid Review complete |
2nd June 2021 |
|
| 24022 |
Copper Coil |
Yanae® Cu-IUD 380 Mini |
Hormone free intrauterine contraception in women of childbearing age |
Rapid Review complete |
27th June 2024 |
|
